Companies › ML Bio Solutions
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Neurology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| BBP-418 substrate supplementation to enhance glycosylation of muscle α-dystroglycan | FKRP | Phase 3 | Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I); LGMD2I | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04800874 | BBP-418 | Phase 2 | LGMD2I | Neurology | Nov 2026 |
| NCT05775848 | BBP-418 | Phase 3 | Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) | Neurology | Sep 2027 |
| NCT07678775 | BBP-418 | Phase 3 | Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I) | Neurology | Oct 2030 |
Bigespas JYAMS PET Research & Development Longboard Pharmaceuticals TriGemX Bio Zogenix
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.